0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
or transfusion-dependent beta thalassemia meet key 12-month endpoints, and it also received a U.S. FDA Commissioner's National Priority Voucher to speed review for this younger age group. This combination of strong pediatric results and accelerated FDA review could meaningfully expand CASGEVY's eligible patient pool and reinforce Vertex's gene-editing credentials. We'll now explore how CASGEVY's strong pediatric data and the FDA's accelerated review voucher may influence Vertex's broader investment narrative. This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality To own Vertex today, you need to believe its CF cash flows can fund a durable transition into gene editing, pain, and kidney disease. The latest CASGEVY pediatric data and priority review voucher support that diversification story and strengthen the near term catalyst around broader CASGEVY uptake, while the biggest ongoing risk is still Vertex's dependence on [Read more]
IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VRTX alerts
from News Quantified
VRTX
NEWS
VRTX
Earnings
VRTX
Analyst Actions
VRTX
SEC Filings
Stockreport

How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated  (VRTX) 
More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
or transfusion-dependent beta thalassemia meet key 12-month endpoints, and it also received a U.S. FDA Commissioner's National Priority Voucher to speed review for this younger age group. This combination of strong pediatric results and accelerated FDA review could meaningfully expand CASGEVY's eligible patient pool and reinforce Vertex's gene-editing credentials. We'll now explore how CASGEVY's strong pediatric data and the FDA's accelerated review voucher may influence Vertex's broader investment narrative. This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality To own Vertex today, you need to believe its CF cash flows can fund a durable transition into gene editing, pain, and kidney disease. The latest CASGEVY pediatric data and priority review voucher support that diversification story and strengthen the near term catalyst around broader CASGEVY uptake, while the biggest ongoing risk is still Vertex's dependence on [Read more]
IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS